Revolution Medicines Analyst Price Targets

Wall Street analyst price targets and consensus rating for Revolution Medicines (RVMD).

Price Target Range — 7 Quarters

Analyst Consensus — 26 Analysts

1S.Buy

24Buy

1Hold

Consensus RatingBuy# Analysts26Avg. Consensus PT$202Upside to Avg. PT+5.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 21, 2026	TD Cowen	Tyler Van Buren	Maintained	Buy	$250
Oct 19, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$240→$241
Oct 16, 2026	William Blair	Alethia Young	Initiate	Outperform	—
Oct 15, 2026	Needham	Ami Fadia	Maintained	Buy	$275
Oct 14, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$259→$260
Oct 8, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$251→$259
Oct 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$239→$240
Sep 28, 2026	Brookline Capital	Leah Rush	Initiate	Buy	$318
Sep 24, 2026	Goldman Sachs	Andrea Newkirk	Reinstates	Buy	$267
Sep 21, 2026	B of A Securities	Alec Stranahan	PT Raise	Buy	$225→$265
Sep 10, 2026	Morgan Stanley	Sean Laaman	Initiate	Overweight	$255
Sep 9, 2026	Stifel	Laura Prendergast	PT Raise	Buy	$215→$230
Aug 31, 2026	Needham	Ami Fadia	PT Raise	Buy	$240→$275
Aug 28, 2026	UBS	Michael Yee	PT Raise	Buy	$220→$265
Aug 28, 2026	Guggenheim	Michael Schmitz	PT Raise	Buy	$240→$275
Aug 27, 2026	Oppenheimer	Jay Olson	PT Raise	Outperform	$230→$260
Aug 27, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$203→$251
Aug 27, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$201→$225
Aug 27, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$231→$239
Aug 27, 2026	Evercore ISI Group	Cory Kasimov	PT Raise	Outperform	$230→$320

Analyst Ratings News

PRO
TD Cowen Reiterates Buy on Revolution Medicines, Announces $250 Price Target

TD Cowen analyst Tyler Van Buren reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $250 price target.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $241

Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $240 to $241.

Benzinga Newsdesk

Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow

William Blair sets $226 price target for Revolution Medicines (RVMD) following Rasonque approval and major oncology expansion plans.

Vandana Singh

PRO
William Blair Initiates Coverage On Revolution Medicines with Outperform Rating

William Blair analyst Alethia Young initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Outperform rating.

Benzinga Newsdesk

PRO
Needham Reiterates Buy on Revolution Medicines, Maintains $275 Price Target

Needham analyst Ami Fadia reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $275 price target.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $260

RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $259 to $260.

Benzinga Newsdesk

Revolution Medicines Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Revolution Medicines Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
TD Cowen Reiterates Buy on Revolution Medicines, Announces $250 Price Target

PRO
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $241

Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow

PRO
William Blair Initiates Coverage On Revolution Medicines with Outperform Rating

PRO
Needham Reiterates Buy on Revolution Medicines, Maintains $275 Price Target

PRO
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $260

People Also Watch

People Also Watch

Revolution Medicines Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Revolution Medicines Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROTD Cowen Reiterates Buy on Revolution Medicines, Announces $250 Price Target

PROTruist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $241

Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow

PROWilliam Blair Initiates Coverage On Revolution Medicines with Outperform Rating

PRONeedham Reiterates Buy on Revolution Medicines, Maintains $275 Price Target

PRORBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $260

People Also Watch

People Also Watch

PRO
TD Cowen Reiterates Buy on Revolution Medicines, Announces $250 Price Target

PRO
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $241

PRO
William Blair Initiates Coverage On Revolution Medicines with Outperform Rating

PRO
Needham Reiterates Buy on Revolution Medicines, Maintains $275 Price Target

PRO
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $260